Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure

What Was Tested

The paper reports a study of Bradykinin in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

Symptomatic hypotension can limit sacubitril/valsartan therapy.

Neprilysin inhibition may augment vasodilators, such as bradykinin.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The participants were allocated by chance, so the Bradykinin group and the comparison group should start out alike.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Bradykinin, giving a reference point.

In the crossover set-up each of the participants took both Bradykinin and the comparison in turn, acting as their own control.

The primary end point was maximal change in mean arterial pressure (MAP).

Plasma natriuretic peptides, urine cyclic GMP, urine volume, sodium excretion, renal plasma flow, and renovascular resistance were measured.

What Was Measured

The subject headings attached to it are Biphenyl Compounds, Aminobutyrates, Heart Failure, Valsartan, Drug Combinations, Tetrazoles and Chronic Disease.

Author keywords: blood pressure, bradykinin, hypotension and neprilysin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin in people with low blood pressure and orthostatic hypotension.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Circulation. Heart failure), a journal based in United States.

More context: the Bradykinin compound page, Low blood pressure and orthostatic hypotension research.